Table 3.
Comparison of efficacy, costs, and cost-effectiveness of erlotinib and pemetrexed in three European markets
| Median OS, months (95% CI)23 | Erlotinib | Pemetrexed | |||||
|---|---|---|---|---|---|---|---|
| 13.9 (10.9–16.8) | 13.4 (11.9–15.9) | ||||||
| France | Germany | Italy | France | Germany | Italy | US | |
| Total monthly per-patient treatment costs, €a | 2140 | 2732 | 1518 | 3453 | 5534 | 2921 | – |
| Cost per LYG, € | 39,783 | 46,931 | 27,885 | – | – | – | $122,371b |
a
Notes: Monthly treatment costs, comprising administration, acquisition, and adverse event costs, are derived from a manuscript in press28 (published in part at a recent scientific conference24,25);
b
cost per LYG for pemetrexed is based on a cost per LYG from the US market,22 which is €86,869 based on an average exchange rate for July 2009 of 0.7098.
Abbreviations: OS, overall survival; CI, confidence interval; LYG, life-year gained.